Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

M, Dimopoulos; A, Spencer; M, Attal; HM, Prince; JL, Harousseau; A, Dmoszynska; Miguel J, San; A, Hellmann; T, Facon; R, Foà; A, Corso; Z, Masliak; M, Olesnyckyj; Z, Yu; J, Patin; JB, Zeldis; RD, Knight

doi:10.1056/nejmoa070594

Public

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Shared by NobleBlocks on Nov 1, 2007 • 12:00 AM UTC

Authors:

Dimopoulos M

Spencer A

Attal M

Abstract

Background Lenalidomide is a structural analogue of thalidomide with similar but more potent biologic activity. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide plus dexamethasone in the treatment of relapsed or refractory multiple myeloma.Methods Of 351 patients who ...

Discussions